Prostacyclin post-treatment improves LPS-induced acute lung injury and endothelial barrier recovery via Rap1

Anna A. Birukova, Fanyong Meng, Yufeng Tian, Angelo Meliton, Nicolene Sarich, Lawrence Quilliam, Konstantin G. Birukov

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Protective effects of prostacyclin (PC) or its stable analog beraprost against agonist-induced lung vascular inflammation have been associated with elevation of intracellular cAMP and Rac GTPase signaling which inhibited the RhoA GTPase-dependent pathway of endothelial barrier dysfunction. This study investigated a distinct mechanism of PC-stimulated lung vascular endothelial (EC) barrier recovery and resolution of LPS-induced inflammation mediated by small GTPase Rap1. Efficient barrier recovery was observed in LPS-challenged pulmonary EC after prostacyclin administration even after 15h of initial inflammatory insult and was accompanied by the significant attenuation of p38 MAP kinase and NFκB signaling and decreased production of IL-8 and soluble ICAM1. These effects were reproduced in cells post-treated with 8CPT, a small molecule activator of Rap1-specific nucleotide exchange factor Epac. By contrast, pharmacologic Epac inhibitor, Rap1 knockdown, or knockdown of cell junction-associated Rap1 effector afadin attenuated EC recovery caused by PC or 8CPT post-treatment. The key role of Rap1 in lung barrier restoration was further confirmed in the murine model of LPS-induced acute lung injury. Lung injury was monitored by measurements of bronchoalveolar lavage protein content, cell count, and Evans blue extravasation and live imaging of vascular leak over 6days using a fluorescent tracer. The data showed significant acceleration of lung recovery by PC and 8CPT post-treatment, which was abrogated in Rap1a-/- mice. These results suggest that post-treatment with PC triggers the Epac/Rap1/afadin-dependent mechanism of endothelial barrier restoration and downregulation of p38MAPK and NFκB inflammatory cascades, altogether leading to accelerated lung recovery.

Original languageEnglish
Pages (from-to)778-791
Number of pages14
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1852
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Acute Lung Injury
Epoprostenol
Lung
Blood Vessels
beraprost
GTP Phosphohydrolases
Therapeutics
Evans Blue
Intercellular Junctions
Monomeric GTP-Binding Proteins
Lung Injury
Bronchoalveolar Lavage
p38 Mitogen-Activated Protein Kinases
Interleukin-8
Pneumonia
Down-Regulation
Nucleotides
Cell Count
Inflammation
Proteins

Keywords

  • Cytoskeleton
  • Endothelium
  • Inflammation
  • Lung
  • Permeability

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Prostacyclin post-treatment improves LPS-induced acute lung injury and endothelial barrier recovery via Rap1. / Birukova, Anna A.; Meng, Fanyong; Tian, Yufeng; Meliton, Angelo; Sarich, Nicolene; Quilliam, Lawrence; Birukov, Konstantin G.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1852, No. 5, 01.05.2015, p. 778-791.

Research output: Contribution to journalArticle

Birukova, Anna A. ; Meng, Fanyong ; Tian, Yufeng ; Meliton, Angelo ; Sarich, Nicolene ; Quilliam, Lawrence ; Birukov, Konstantin G. / Prostacyclin post-treatment improves LPS-induced acute lung injury and endothelial barrier recovery via Rap1. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2015 ; Vol. 1852, No. 5. pp. 778-791.
@article{c1643c645099489a9715ab7e92bfc273,
title = "Prostacyclin post-treatment improves LPS-induced acute lung injury and endothelial barrier recovery via Rap1",
abstract = "Protective effects of prostacyclin (PC) or its stable analog beraprost against agonist-induced lung vascular inflammation have been associated with elevation of intracellular cAMP and Rac GTPase signaling which inhibited the RhoA GTPase-dependent pathway of endothelial barrier dysfunction. This study investigated a distinct mechanism of PC-stimulated lung vascular endothelial (EC) barrier recovery and resolution of LPS-induced inflammation mediated by small GTPase Rap1. Efficient barrier recovery was observed in LPS-challenged pulmonary EC after prostacyclin administration even after 15h of initial inflammatory insult and was accompanied by the significant attenuation of p38 MAP kinase and NFκB signaling and decreased production of IL-8 and soluble ICAM1. These effects were reproduced in cells post-treated with 8CPT, a small molecule activator of Rap1-specific nucleotide exchange factor Epac. By contrast, pharmacologic Epac inhibitor, Rap1 knockdown, or knockdown of cell junction-associated Rap1 effector afadin attenuated EC recovery caused by PC or 8CPT post-treatment. The key role of Rap1 in lung barrier restoration was further confirmed in the murine model of LPS-induced acute lung injury. Lung injury was monitored by measurements of bronchoalveolar lavage protein content, cell count, and Evans blue extravasation and live imaging of vascular leak over 6days using a fluorescent tracer. The data showed significant acceleration of lung recovery by PC and 8CPT post-treatment, which was abrogated in Rap1a-/- mice. These results suggest that post-treatment with PC triggers the Epac/Rap1/afadin-dependent mechanism of endothelial barrier restoration and downregulation of p38MAPK and NFκB inflammatory cascades, altogether leading to accelerated lung recovery.",
keywords = "Cytoskeleton, Endothelium, Inflammation, Lung, Permeability",
author = "Birukova, {Anna A.} and Fanyong Meng and Yufeng Tian and Angelo Meliton and Nicolene Sarich and Lawrence Quilliam and Birukov, {Konstantin G.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.bbadis.2014.12.016",
language = "English",
volume = "1852",
pages = "778--791",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Prostacyclin post-treatment improves LPS-induced acute lung injury and endothelial barrier recovery via Rap1

AU - Birukova, Anna A.

AU - Meng, Fanyong

AU - Tian, Yufeng

AU - Meliton, Angelo

AU - Sarich, Nicolene

AU - Quilliam, Lawrence

AU - Birukov, Konstantin G.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Protective effects of prostacyclin (PC) or its stable analog beraprost against agonist-induced lung vascular inflammation have been associated with elevation of intracellular cAMP and Rac GTPase signaling which inhibited the RhoA GTPase-dependent pathway of endothelial barrier dysfunction. This study investigated a distinct mechanism of PC-stimulated lung vascular endothelial (EC) barrier recovery and resolution of LPS-induced inflammation mediated by small GTPase Rap1. Efficient barrier recovery was observed in LPS-challenged pulmonary EC after prostacyclin administration even after 15h of initial inflammatory insult and was accompanied by the significant attenuation of p38 MAP kinase and NFκB signaling and decreased production of IL-8 and soluble ICAM1. These effects were reproduced in cells post-treated with 8CPT, a small molecule activator of Rap1-specific nucleotide exchange factor Epac. By contrast, pharmacologic Epac inhibitor, Rap1 knockdown, or knockdown of cell junction-associated Rap1 effector afadin attenuated EC recovery caused by PC or 8CPT post-treatment. The key role of Rap1 in lung barrier restoration was further confirmed in the murine model of LPS-induced acute lung injury. Lung injury was monitored by measurements of bronchoalveolar lavage protein content, cell count, and Evans blue extravasation and live imaging of vascular leak over 6days using a fluorescent tracer. The data showed significant acceleration of lung recovery by PC and 8CPT post-treatment, which was abrogated in Rap1a-/- mice. These results suggest that post-treatment with PC triggers the Epac/Rap1/afadin-dependent mechanism of endothelial barrier restoration and downregulation of p38MAPK and NFκB inflammatory cascades, altogether leading to accelerated lung recovery.

AB - Protective effects of prostacyclin (PC) or its stable analog beraprost against agonist-induced lung vascular inflammation have been associated with elevation of intracellular cAMP and Rac GTPase signaling which inhibited the RhoA GTPase-dependent pathway of endothelial barrier dysfunction. This study investigated a distinct mechanism of PC-stimulated lung vascular endothelial (EC) barrier recovery and resolution of LPS-induced inflammation mediated by small GTPase Rap1. Efficient barrier recovery was observed in LPS-challenged pulmonary EC after prostacyclin administration even after 15h of initial inflammatory insult and was accompanied by the significant attenuation of p38 MAP kinase and NFκB signaling and decreased production of IL-8 and soluble ICAM1. These effects were reproduced in cells post-treated with 8CPT, a small molecule activator of Rap1-specific nucleotide exchange factor Epac. By contrast, pharmacologic Epac inhibitor, Rap1 knockdown, or knockdown of cell junction-associated Rap1 effector afadin attenuated EC recovery caused by PC or 8CPT post-treatment. The key role of Rap1 in lung barrier restoration was further confirmed in the murine model of LPS-induced acute lung injury. Lung injury was monitored by measurements of bronchoalveolar lavage protein content, cell count, and Evans blue extravasation and live imaging of vascular leak over 6days using a fluorescent tracer. The data showed significant acceleration of lung recovery by PC and 8CPT post-treatment, which was abrogated in Rap1a-/- mice. These results suggest that post-treatment with PC triggers the Epac/Rap1/afadin-dependent mechanism of endothelial barrier restoration and downregulation of p38MAPK and NFκB inflammatory cascades, altogether leading to accelerated lung recovery.

KW - Cytoskeleton

KW - Endothelium

KW - Inflammation

KW - Lung

KW - Permeability

UR - http://www.scopus.com/inward/record.url?scp=84922572970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922572970&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2014.12.016

DO - 10.1016/j.bbadis.2014.12.016

M3 - Article

VL - 1852

SP - 778

EP - 791

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 5

ER -